Hackensack Meridian Health and Pharma Partnerships

Hackensack Meridian Health (HMH) is a non-profit healthcare system based in Edison, New Jersey, and one of the largest in the United States by hospital count, operating seventeen hospitals and a network of more than 500 patient care locations across the state. As of 2023, the organization reported $7.5 billion in annual revenue. Its scale has made it a significant partner for pharmaceutical and biotechnology companies seeking clinical research infrastructure, patient populations for trials, and translational research expertise. The partnerships HMH has formed with pharmaceutical and life sciences firms represent a substantial portion of New Jersey's broader biomedical research activity, with implications for drug development, workforce training, healthcare delivery models, and community access to experimental treatments.

The economic and social reach of these collaborations extends well beyond any single hospital campus. They have influenced local employment, real estate investment, academic programming, and the demographic composition of research cohorts in northern and central New Jersey. Community concern about market consolidation—HMH and RWJBarnabas Health together dominate much of the state's hospital market—runs alongside these research achievements and is part of the complete picture of what these partnerships mean for New Jersey residents.

History

Hackensack University Medical Center traces its origins to 1888, when it was founded as a community hospital in Bergen County. The modern Hackensack Meridian Health system took shape through the 2016 merger of Hackensack University Health Network and Meridian Health, forming one of the most integrated healthcare networks on the East Coast. The letter of intent for that merger was signed in 2015, and the formal combination was completed in 2016. The consolidation was driven by the need to improve clinical outcomes, contain costs, and expand access to specialized care across a geographically diverse service area stretching from Bergen County to the Jersey Shore.

The organization's research ambitions were given institutional form with the establishment of the Center for Discovery and Innovation (CDI), which became HMH's flagship translational research engine. Located in Nutley, New Jersey, on the former Roche campus, the CDI recruits scientists working across oncology, infectious disease, and microbiology, and serves as the primary vehicle through which HMH executes pharmaceutical and biotechnology licensing agreements. Its founding represented a deliberate shift from a hospital system focused primarily on clinical care toward one with an active drug discovery and development program.

Earlier pharma-adjacent initiatives included the Hackensack Meridian Health Institute for Innovation and Entrepreneurship, established in 2016 on the Hackensack University Medical Center campus. That institute was conceived as a meeting point for clinicians, researchers, and industry partners, with the goal of moving discoveries from bench to bedside more quickly. It set the organizational precedent for the deeper research partnerships that would follow through the CDI.

Research Partnerships

Center for Discovery and Innovation

The Center for Discovery and Innovation is the institutional anchor for HMH's pharmaceutical partnerships. Based in Nutley in a facility that previously housed Roche's U.S. research headquarters, the CDI brings together over 200 scientists and clinicians working on projects spanning antimicrobial resistance, cancer biology, and fungal infections. Its location in New Jersey's established pharmaceutical corridor—proximate to the former headquarters of Roche, Novartis, and Hoffmann-La Roche—gives it access to a dense network of industry contacts and experienced research talent.

In November 2025, HMH's CDI and researchers from Johns Hopkins University were awarded major federal funding to study fungal infections, a historically under-resourced area of infectious disease research. The grant supports work on invasive fungal diseases that disproportionately affect immunocompromised patients, including those undergoing cancer treatment or organ transplantation. It is among the more visible examples of CDI's role in attracting competitive federal research dollars to New Jersey.

BioVersys Partnership (2024)

In 2024, HMH's Center for Discovery and Innovation entered into an exclusive collaboration and licensing agreement with BioVersys, a Belgian clinical-stage biotechnology company focused on antimicrobial resistance. The agreement centers on a portfolio of novel ansamycin antibiotic compounds developed at the CDI, which BioVersys licensed to advance as treatments for non-tuberculous mycobacteria (NTM) infections.

NTM infections are caused by environmental mycobacteria and are notoriously difficult to treat, particularly in patients with structural lung disease or compromised immune systems. Existing antibiotic regimens are lengthy, toxic, and frequently fail to achieve durable cures. The ansamycin compounds developed at CDI represent a distinct chemical class with a different mechanism of action than current standard-of-care drugs, giving BioVersys a potential path to differentiated NTM therapies. The deal exemplifies a model in which an academic medical center's internal research program generates intellectual property that is then licensed to an industry partner for clinical development—a structure that allows HMH to capture some financial return on its research investment while transferring development risk to a company with drug-development expertise.

Lumeris Value-Based Care Partnership

Not all of HMH's industry partnerships involve drug development. In January 2026, HMH announced the expansion of its longstanding partnership with Lumeris, a health technology and managed care company, to include traditional Medicare populations in addition to the Medicare Advantage patients the two organizations had worked with previously. The agreement focuses on value-based care delivery, a model under which providers are reimbursed based on patient outcomes rather than the volume of services rendered.

The Lumeris partnership is operationally distinct from HMH's pharmaceutical research collaborations. Its goal is to reduce unnecessary hospitalizations, improve chronic disease management, and lower total cost of care for Medicare beneficiaries. For a system of HMH's size, the ability to manage large populations under value-based contracts depends on data infrastructure, care coordination staffing, and physician alignment—all areas where Lumeris provides technology and analytical support. The expansion to traditional Medicare is significant because that population tends to be older, sicker, and more costly than Medicare Advantage enrollees, and it represents a much larger share of HMH's patient base.

AI and Digital Health

HMH has also moved into artificial intelligence-driven care delivery. In 2025, the organization began deploying Ekam, an AI tool built on Google Cloud infrastructure, with nurses serving as the primary operational users. The rollout was structured around a nurse ambassador program designed to build frontline clinical trust in the technology before broader deployment. Ekam is intended to reduce administrative burden, assist with documentation, and surface relevant clinical information at the point of care. The partnership reflects a broader industry trend toward embedding AI tools in hospital workflows, with HMH among the earlier large New Jersey systems to do so at scale.

Economy

The economic footprint of HMH's pharmaceutical and industry partnerships is substantial. The organization itself reported $7.5 billion in annual revenue in 2023 and is among New Jersey's largest private employers. Healthcare and pharmaceutical activity in the state, taken together, accounts for a significant share of gross state product, and HMH's research partnerships contribute to that total through direct research spending, employment of scientists and clinical research staff, and licensing income generated by CDI discoveries.

The location of the CDI on the former Roche campus in Nutley has been an economic development story in its own right. That site, which sat largely vacant after Roche consolidated its U.S. operations, has been revitalized through HMH's occupancy and the co-location of additional life sciences tenants. The presence of an active research institution with pharmaceutical licensing agreements makes the site attractive to biotech startups and contract research organizations looking for proximity to both talent and clinical research infrastructure.

Indirect economic effects include spending by research employees in surrounding communities, demand for specialized vendors such as laboratory equipment suppliers and contract manufacturing organizations, and the attraction of venture capital to New Jersey-based companies emerging from HMH's research programs. The BioVersys licensing deal, for instance, puts a Belgian company's drug development dollars to work on compounds originated in New Jersey, with ongoing collaborative research conducted at the CDI.

Community concern about market consolidation accompanies these economic benefits. New Jersey residents and healthcare observers have noted that HMH and RWJBarnabas Health together operate the majority of the state's acute care hospital beds, limiting competitive options in many parts of the state. Critics have argued that consolidation can reduce price competition and limit patient choice, while the organizations themselves argue that scale is necessary to sustain the infrastructure required for advanced research and specialized care.

Education

HMH's industry collaborations have had a direct effect on medical education and research training in New Jersey. The organization has partnerships with Seton Hall University's Hackensack Meridian School of Medicine, which was established in part to give HMH a dedicated pipeline of physicians trained within the system's clinical and research culture. The medical school, located in Nutley adjacent to the CDI campus, integrates research exposure into its curriculum from the first year, and students have access to ongoing studies at the CDI as part of their training.

The CDI's proximity to the medical school has created opportunities for students and postdoctoral researchers to work directly alongside scientists pursuing pharmaceutical licensing agreements, including the antimicrobial resistance research underlying the BioVersys deal. Fellowships and residency programs affiliated with HMH hospitals have incorporated pharmaceutical research rotations, and the organization has funded scholarships in pharmacy, biomedical engineering, and public health through its academic affiliates.

The New Jersey Institute of Technology and other regional universities have also maintained research relationships with HMH, particularly in areas requiring engineering and data science expertise. These arrangements allow HMH to access capabilities that a hospital system doesn't develop internally—computational biology, medical device prototyping, and health data analytics—while giving university researchers access to clinical data and patient populations that academic labs alone can't obtain.

Demographics

The communities served by HMH's research programs reflect New Jersey's demographic diversity. Bergen County, home to Hackensack University Medical Center, had a population of over 950,000 as of the 2020 U.S. Census, with a median age of 41.3 and substantial Hispanic, Asian, and African American populations. Hudson County, where HMH also operates facilities, is among the most densely populated and ethnically diverse counties in the United States. The northern New Jersey corridor where HMH is most concentrated is home to large immigrant communities, including South Asian populations in Bergen and Middlesex counties and Latin American communities throughout Hudson County.

This demographic context matters for pharmaceutical research. Clinical trial diversity has been a documented problem in drug development nationally, with many trials historically enrolling patient populations that don't reflect the racial and ethnic composition of the people who will ultimately take the drugs being tested. HMH's geographic position within one of the country's most diverse metropolitan areas gives its research programs access to patient populations that many trial sites—particularly those at academic medical centers in less diverse regions—can't match. HMH has cited diversity in clinical trial enrollment as a priority, and partnerships like the one with Merck have included outreach components designed to ensure broader representation.

Research workforce demographics have also shifted as HMH has grown its research enterprise. The CDI and affiliated programs have attracted scientists and clinical researchers to New Jersey, including professionals from international pharmaceutical companies that previously operated research facilities in the state. Women and researchers from underrepresented groups have participated in CDI programs, though the organization has not published detailed workforce diversity data that would allow independent assessment of progress in this area.

Controversies and Community Concerns

HMH's growth and non-profit status have attracted scrutiny. The organization's $7.5 billion in 2023 revenue, combined with its tax-exempt status, has prompted questions from patient advocates and policy observers about the balance between community benefit obligations and financial performance. Non-profit hospitals in New Jersey, as elsewhere, are required to provide community benefit in exchange for their tax exemption, and HMH reports community benefit spending annually—but the adequacy of such spending relative to the tax benefits received is an ongoing subject of debate in healthcare policy circles.

Billing practices have generated complaints from patients in New Jersey. HMH operates paramedic services that are dispatched under state protocols for specific chief complaints including altered mental status, diabetic emergencies, and respiratory distress. Patients have reported receiving bills for paramedic assessments even when no treatment was administered and no transport occurred—a billing practice that is legal under New Jersey regulations but that many patients don't anticipate. The charges reflect the cost of deploying advanced life support personnel, regardless of whether the encounter results in transport to a hospital.

Primary care access is a related concern. Bergen and Hudson County residents have noted difficulty accessing primary care appointments with HMH-affiliated physicians, with many practices limiting availability for acute sick visits and directing patients toward urgent care centers or emergency rooms instead. This dynamic, which accelerated during the COVID-19 pandemic and hasn't fully reversed, affects how patients interact with the system and has implications for the communities in which HMH conducts pharmaceutical research.

Market consolidation is perhaps the broadest concern. The combination of HMH's seventeen hospitals and RWJBarnabas's network means that most New Jersey residents outside of the Philadelphia suburbs and a few independent hospital markets have limited alternatives for acute care. Health economists have documented price and quality effects from hospital consolidation nationally, and New Jersey has been cited as an example of a state where consolidation has proceeded further than in many others.